6 completed, 2 terminated. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 6, Terminated 2 |
Follow ixabepilone: new trials by email Literature Review of ixabepilone trials Research Report on ixabepilone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine NKTR-102, Eribulin, Ixabepilone - Metastasis, Breast Cancer | Phase 3 | Completed | Nektar Therapeutics | 178 | 2016-11-01 | 2023-04-14 |
| Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer Calcium Gluconate, Magnesium Sulfate, Placebo - Neuropathy, Pain | Phase 3 | Terminated | Mayo Clinic | 1 | 2009-11-01 | 2016-02-04 |
| A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer Ixabepilone, Doxorubicin, Paclitaxel - Endometrial Cancer | Phase 3 | Terminated | R-Pharm | 551 | 2009-08-01 | 2017-03-09 |
| A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra) - Breast Cancer | Phase 3 | Completed | SCRI Development Innovations, LLC | 614 | 2008-12-01 | 2017-07-02 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 3 | Completed | National Cancer Institute (NCI) | 799 | 2008-10-13 | 2026-06-23 |
| Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer cyclophosphamide, Docetaxel, epirubicin hydrochloride - Breast Cancer | Phase 3 | Completed | UNICANCER | 762 | 2007-09-01 | 2024-02-21 |
| Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Ixabepilone + Capecitabine, Capecitabine - Cancer, Breast Cancer | Phase 3 | Completed | R-Pharm | 1221 | 2003-11-01 | 2020-11-02 |
| Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Ixabepilone + Capecitabine, Capecitabine - Breast Cancer, Metastases | Phase 3 | Completed | R-Pharm | 752 | 2003-09-01 | 2020-11-02 |
Breast Neoplasms (7) · Neoplasm Metastasis (2) · Carcinoma (1) · Endometrial Neoplasms (1) · Neoplasms (1) · Pain (1)
R-Pharm (3) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Nektar Therapeutics (1) · SCRI Development Innovations, LLC (1) · UNICANCER (1)
United States (8) · Belgium (5) · France (5) · Canada (4) · Italy (4) · Spain (4) · United Kingdom (4) · Argentina (3) · Australia (3) · Brazil (3) · Greece (3) · China (2) · Czechia (2) · Denmark (2) · Germany (2)
Charles Loprinzi (1) · Denise A Yardley, M.D. (1) · Hope S Rugo (1) · Mario Campone, MD (1)
PMID 21128114, PMID 21937232, PMID 24472478, PMID 17968020, PMID 25925990, PMID 26056183, PMID 28620884, PMID 29522361, PMID 31074641, PMID 34616010, PMID 35552364, PMID 39169033
2008 (1), P30CA015083 (1), U10CA031946 (1), U10CA180821 (1)